Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 629 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: quinolone Clear all

Conditions: Bacterial Conjunctivitis
Interventions: Gatifloxacin 0.5% eye drops, placebo eye drops; Drug
Lead sponsor: Allergan; Industry
Eligibility: 1 Year and older
Enrollment: 859 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Downey, California

Conditions: Electrocardiogram Repolarisation Abnormality, Gonococcal Infection
Interventions: AZD0914, Moxifloxacin, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Pharmacokinetics of Isavuconazole, Healthy Volunteers
Interventions: Isavuconazole, Placebo, Moxifloxacin; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 161 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Glendale, California

Conditions: Pharmacokinetics
Interventions: monophasic oral contraceptive, AZD7325; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Community Acquired Pneumonia in Children
Interventions: Ampicillin for Injection, Ceftriaxone for Injection, Amoxicillin, Ampicillin / Sulbactam Injection, Amoxicillin-clavulanate, Clindamycin, Cefprozil, Levofloxacin; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 3 Months to 18 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Schizophrenia, Mental Disorder, Nervous System Diseases
Interventions: Aripiprazole, OPC-14597; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 11
States / cities: Cerritos, California • Garden Grove, California • San Diego, California + 8 more

Conditions: Bipolar Disorder
Interventions: Aripiprazole; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Corneal Transplantation
Interventions: 1.5% levofloxacin ophthalmic solution, 0.5% moxifloxacin ophthalmic solution; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 8
States / cities: Boynton Beach, Florida • Indianapolis, Indiana • Great Rapids, Michigan + 5 more

Conditions: Advanced Cancer
Interventions: SGX523 Capsules; Drug
Lead sponsor: SGX Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Santa Monica, California • Nashville, Tennessee

Conditions: Urinary Tract Infections
Interventions: Cipro XR (Ciprofloxacin, BAYQ3939); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 35
States / cities: Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 30 more

Conditions: Infection
Interventions: Ciprofloxacin, trimethoprim-sulfamethoxazole, cefuroxime, ceftriaxone, gentamicin, amikacin, aztreonam, imipenem; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 30 Years to 90 Years · Male only
Enrollment: 563 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Influenza, Human
Interventions: 600 mg zanamivir + moxifloxacin placebo, 1200 mg zanamivir + moxifloxacin placebo, zanamivir placebo + moxifloxacin placebo, zanamivir placebo + 400 mg moxifloxacin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: CXA-101/tazobactam, Moxifloxacin, placebo; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 45 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: TQT Study
Interventions: Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo, Moxifloxacin 400mg, Placebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr), Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr); Drug · Other
Lead sponsor: Spero Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Bilateral Middle Ear Effusion Requiring Tympanostomy Tube Placement
Interventions: OTO-201, Placebo, Sham; Drug
Lead sponsor: Otonomy, Inc.; Industry
Eligibility: 6 Months to 12 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: San Diego, California

Conditions: Colorectal Cancer, CRC
Interventions: Standard of Care Chemotherapy + Metronidazole, ciprofloxacin, aspirin; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 2
States / cities: Richmond, Virginia

Conditions: Systemic Lupus Erythematosus, Healthy Participants
Interventions: BMS-986165, Moxifloxacin, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Bipolar I
Interventions: Aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 748 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 72
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 62 more

Conditions: Urolithiasis, UTI
Interventions: Ciprofloxacin, trimethoprim/sulfamethoxazole, No Intervention; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: Not listed
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Bacterial Infections
Interventions: Ciprofloxacin single dose, Ciprofloxacin triple dose; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 497 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 18
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 15 more

Conditions: QTc Interval, Pharmacokinetics
Interventions: Psilocybin, Moxifloxacin, Micro-Crystalline Cellulose; Drug
Lead sponsor: Usona Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Risperidone microspheres, Risperidone, Olanzapine, Quetiapine, Ziprasidone, Aripiprazole, Paliperidone; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 8
States / cities: Los Angeles, California • Augusta, Georgia • Iowa City, Iowa + 5 more

Conditions: HIV Infections, Tuberculosis
Interventions: Isoniazid, Pyridoxine hydrochloride, Levofloxacin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Torrance, California + 7 more

Conditions: Bipolar Disorder
Interventions: aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: Philadelphia, Pennsylvania • Austin, Texas • Bellaire, Texas + 1 more

Search by objective public record fields.

A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis

Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects

Study of the Effect of Repeat Doses of Isavuconazole on Cardiac Repolarization

Determine the Effects of C-administration of AZD7325 and an Oral Contraceptive in Healthy Female Subjects

Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP

Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia

12- Week Open Label Treatment of Refractory Bipolar Depression

Ocular Penetration of 1.5% Levofloxacin and 0.5% Moxifloxacin During Corneal Transplant Surgery

Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors

Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens

Antibiotic Prophylaxis for Transrectal Prostate Biopsy

A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers

Safety Study Designed to Study the Effects of Two Different Doses of CXA-101/Tazobactam, a Low Dose and a High Dose, on the QT/QTc Intervals in Healthy Subjects

A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects

OTO-201 for Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement

Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer

An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects

Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder

Antibiotic Prophylaxis With Routine Ureteral Stent Removal

BAYQ3939, 1000 mg Tablet in Transrectal Needle Biopsies of the Prostate (TRNBP) - Infection Prophylaxis

An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics

Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy

A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin

Drug-drug Interaction Study of Aripiprazole and Lamotrigine in Patients With Bipolar Type I Disorder